Laurus Labs gets approval from FDA
In Short
Pharma major Laurus Labs received an Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its API Units 1 & 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.

Hyderabad: Pharma major Laurus Labs received an Establishment Inspection Report (EIR) from US Food and Drug Administration (USFDA) for its API Units 1 & 3, located at Parawada, Visakhapatnam, for the inspection conducted in June 2019.
In the FDF segment, the company received Global Fund (GF) ERP (Expert Review Panel) approval for FDC (Fixed Dose Combination) TLE 400 (Tenofovir/Lamivudine/Efavirenz 300/ 300/ 400mg) for supply in GF funded projects.
Laurus Labs is one among the three companies to receive the approval for this product in ART (Anti Retro Viral Therapy).
This approval enables Laurus Labs to participate directly in GF and also In-Country tenders based on GF funding across Sub-Saharan African region along with our other ARV portfolio comprising of TLD (Tenofovir/ Lamivudine/ Dolutegravir 300/300/50mg), DTG (Dolutegravir 50mg) and ET (Emtricitabine/Tenofovir 200/300mg).
Dulquer Salmaan’s ‘Aakasamlo Oka Tara’ Telugu Trailer Is Out…
Father-son duo rescued from drowning in Ganga during Chhath Puja in Haridwar
‘Those runs were game-changers,’ says Arshdeep Singh on late cameo with bat
South Korea's Lee proposes initiative with ASEAN to ensure AI benefits for all
Mekedatu Test for Vijay: Will He Take Up Tamil Nadu's Cause with Sonia
"It Was Between Modibhai and Me, Not Congress and BJP": Pitroda
Another Severe Cyclone Threatens AP; Fishermen Told Not to Venture into Sea till November 19
BJP-SAD alliance nears final shape: BJP seeks 40 seats; formal announcement likely on Nov 24
Jay Shah Reappointed As ICC Chairman For Second Term, Elected Unopposed
PM Modi heads to Philippines for ASEAN-India, East Asia summits, says it will impart new energy to ties

